Guides Collective
The Weekly Guide 2
Resources, research, and reflections — curated each week for the guides in our community.
MAY 22, 2026
Section 01
Industry Headlines
What's happening in the psychedelic space this week.
THE HILL · MAY 19, 2026
'The Time Is Now': Congress Pushes for Psychedelic Treatment Breakthroughs
Rep. Jack Bergman, the highest-ranking combat veteran in Congress and co-chair of the bipartisan PATH Caucus, called on lawmakers to advance psychedelic-assisted therapy, introducing legislation to establish VA centers dedicated to MDMA, ibogaine, and ketamine research for veterans.
LUCID NEWS · MAY 11, 2026
PsyCon Denver 2026: Modern Psychedelia Braces for What Comes Next
The modern psychedelic renaissance navigated rapid expansion and shifting legislation at PsyCon Denver, where tension between legitimate industry development and gray-market commercialization offered a candid look at where the field stands.
EMORY UNIVERSITY · APRIL 29, 2026
Emory Joins Landmark $21 Million NIH Study of Psychedelics for Chronic Pain in Older Adults
The INSPIRE Network, the first federally funded clinical research program focused specifically on psychedelics in adults 65 and older, is now active, with Emory receiving $4 million to study psilocybin and LSD for treating chronic pain.
Section 02
From the Field
Perspectives and insights from leaders in the psychedelic space.
Josh Hardman · Psychedelic Alpha
"If I Can't Change My Views Based on Evidence, Then Why Do Science at All?" — Nora Volkow on Psychedelics
Nora Volkow, Director of the National Institute on Drug Abuse since 2003, presented at the APA annual meeting in San Francisco — drawing standing-room-only crowds with a long-awaited shift in her public stance on psychedelics.
Josh Hardman · Psychedelic Alpha
Psilocybin for Chronic Suicidal Ideation: Scott T. Aaronson on Safety, an Efficacy Signal, and the Role of Expectations
Psychiatrist Scott T. Aaronson studied twenty adults with chronic suicidal ideation who received a single 25mg dose of COMP360 psilocybin. Results showed substantial reductions in suicidal ideation sustained through 12 weeks — with no serious adverse events reported.
Section 03
Personal Journeys
First-person accounts worth reading — perspectives that inform the work we do.
STAT NEWS · FEBRUARY 19, 2026
I Took Part in a 2012 Psilocybin Trial. What I'm Seeing Now Horrifies Me.
Author and trial participant Erica Rex argues that for-profit companies are stripping psychedelic therapy of the guides and ceremonial context that made it transformative — replacing them with one-on-one sessions optimized for scalability over safety.
NORMALIZE PSYCHEDELICS · JANUARY 23, 2026
What Changed After 38 Years Sober: Linda's First Psychedelic Experience
At 65, Linda reflects on her first intentional psilocybin journey after nearly four decades of sobriety — how it helped her release long-held anger, step away from her business with newfound calm, and discover microdosing as a daily integration practice.
Section 04
From the Platform
What's new and coming to Guides Collective.
New facilitator profiles are live — guides can now showcase their modalities, specialties, and approach to preparation and integration support.
The match column on your dashboard is now removed! Only seekers who have scheduled a call with you will now appear.